A bioorthogonal-catalytic artificial antigen-presenting cell for chemo- and immuno-therapy.

Zhengwei Liu, Wenting Zhang, Chuanqi Zhao, Mengyu Sun, Jinsong Ren, Xiaogang Qu

Abstract read

In one paragraph

Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhengwei LiuLaboratory of Chemical Biology, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China xqu@ciac.ac.cn.

Wenting ZhangLaboratory of Chemical Biology, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China xqu@ciac.ac.cn.

Chuanqi ZhaoLaboratory of Chemical Biology, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China xqu@ciac.ac.cn.

Mengyu SunLaboratory of Chemical Biology, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China xqu@ciac.ac.cn.

Jinsong RenLaboratory of Chemical Biology, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China xqu@ciac.ac.cn.ORCID https://orcid.org/0000-0002-7506-627X

Xiaogang QuLaboratory of Chemical Biology, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China xqu@ciac.ac.cn.ORCID https://orcid.org/0000-0003-2868-3205

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioorthogonal prodrug activation has emerged as a promising strategy in tumor therapy. However, its clinical translation is hindered by limited therapeutic efficacy due to the complexity of tumors and heterogeneity of individuals. Herein, an artificial antigen-presenting cell (aAPC)-based biomimetic bioorthogonal catalyst is developed by encapsulating transition metal catalysts (TMCs) within lipid nanoparticles cloaked with dendritic cell membranes (LNP-Fe@dcM). By imitating key immune cell functions, LNP-Fe@dcM mediates a dual-mode antitumor response

Identifiers

PMID41283147

DOI10.1039/d5sc06284e

PMCPMC12637043

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.